
Cigna is swapping an insurance company for a specialty drug business, and it keeps raising 2026 guidance while openly accepting that 2027 is the year the pharmacy rebuild costs it earnings. How much of Cigna's 2027 EPS growth comes from the $3 billion cost program?
Biosimilars and specialty generics, with Revlimid now about 90% penetrated, shift profit out of the pharmacy benefit business into Specialty & Care, roughly a third of company income. That is where the capital is going. Which 2028 biosimilar launches does Cigna expect to refill specialty growth?
It exits the individual exchange at the end of 2026 and has put eviCore up for review, after selling Medicare. The exit resets the 2027 earnings starting point to roughly $30 a share, so growth must now come from US employers.
Pharmacy benefit profit fell 28% in Q1 on client renewals and Signature spending that runs through 2027. Management guides the segment down again in 2027 as rebate pools shrink; the payoff is adoption in 2028. What margin does Cigna expect from Signature once half of clients adopt it?
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$1K | Aug 28 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$100K | Jul 20 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jul 8 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 24 | Aug 22 |
Donald Trump Republican · Executive | Purchase | ≥$100K | May 18 | Jul 1 |
Congressional trading data provided by QuiverQuant
How Cigna turned $275B of revenue into $9.2B of operating income.
| Revenue | ||
|---|---|---|
| Evernorth | $235B | ▲ 18.56% YoY |
| Cigna Healthcare | $47.4B | ▼ 0.24% YoY |
| Total revenue | $275B | |
| Operating income | $9.2B | 3.3% |